Cancer Metabolism: Molecular Targeting and Implications for Therapy

Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors valida...

Full description

Saved in:
Bibliographic Details
Superior document:Frontiers Research Topics
:
Year of Publication:2017
Language:English
Series:Frontiers Research Topics
Physical Description:1 electronic resource (114 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 03653nam-a2200373z--4500
001 993543894104498
005 20230221133615.0
006 m o d
007 cr|mn|---annan
008 202102s2017 xx |||||o ||| eneng d
035 |a (CKB)4100000002484755 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/42642 
035 |a (EXLCZ)994100000002484755 
041 0 |a eng 
100 1 |a Shanmugasundaram Ganapathy-Kanniappan  |4 auth 
245 1 0 |a Cancer Metabolism: Molecular Targeting and Implications for Therapy 
246 |a Cancer Metabolism 
260 |b Frontiers Media SA  |c 2017 
300 |a 1 electronic resource (114 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers Research Topics 
520 |a Development of an effective anticancer therapeutic necessitates the selection of cancer-related or cancer-specific pathways or molecules that are sensitive to intervention. Several such critical yet sensitive molecular targets have been recognized, and their specific antagonists or inhibitors validated as potential therapeutics in preclinical models. Yet, majority of anticancer principles or therapeutics show limited success in the clinical translation. Thus, the need for the development of an effective therapeutic strategy persists. “Altered energy metabolism” in cancer is one of the earliest known biochemical phenotypes which dates back to the early 20th century. The German scientist, Otto Warburg and his team (Warburg, Wind, Negelein 1926; Warburg, Wind, Negelein 1927) provided the first evidence that the glucose metabolism of cancer cells diverge from normal cells. This phenomenal discovery on deregulated glucose metabolism or cellular bioenergetics is frequently witnessed in majority of solid malignancies. Currently, the altered glucose metabolism is used in the clinical diagnosis of cancer through positron emission tomography (PET) imaging. Thus, the “deregulated bioenergetics” is a clinically relevant metabolic signature of cancer cells, hence recognized as one of the hallmarks of cancer (Hanahan and Weinberg 2011). Accumulating data unequivocally demonstrate that, besides cellular bioenergetics, cancer metabolism facilitates several cancer-related processes including metastasis, therapeutic resistance and so on. Recent reports also demonstrate the oncogenic regulation of glucose metabolism (e.g. glycolysis) indicating a functional link between neoplastic growth and cancer metabolism. Thus, cancer metabolism, which is already exploited in cancer diagnosis, remains an attractive target for therapeutic intervention as well. The Frontiers in Oncology Research Topic “Cancer Metabolism: Molecular Targeting and Implications for Therapy” emphases on recent advances in our understanding of metabolic reprogramming in cancer, and the recognition of key molecules for therapeutic targeting. Besides, the topic also deliberates the implications of metabolic targeting beyond the energy metabolism of cancer. The research topic integrates a series of reviews, mini-reviews and original research articles to share current perspectives on cancer metabolism, and to stimulate an open forum to discuss potential challenges and future directions of research necessary to develop effective anticancer strategies. 
546 |a English 
653 |a Tumor microenvironment 
653 |a metastasis 
653 |a Cancer Metabolism 
653 |a glycolysis 
653 |a immunotherapy 
653 |a epigenetic regulation 
653 |a metabolic reprogramming 
653 |a Warburg effect 
776 |z 2-88945-322-7 
906 |a BOOK 
ADM |b 2023-03-03 01:52:09 Europe/Vienna  |f system  |c marc21  |a 2018-03-10 17:16:05 Europe/Vienna  |g false 
AVE |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337440820004498&Force_direct=true  |Z 5337440820004498  |8 5337440820004498